Pfizer stock gains on strong India margin and global earnings beat

Published on 09/03/2026 at 07:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock is drawing investor interest as Pfizer Limited in India posts a net profit margin above 30 percent and the global group beats second quarter 2026 earnings expectations while raising full year guidance.

Pfizer, INE182A01018, Illustration mit AI erstellt.

The pharmaceutical group Pfizer Limited (ISIN INE182A01018) stock is in focus as of September 3, 2026, with the India unit showing a net profit margin of 31.79 percent for the June 2025 quarter and the global group delivering a second quarter 2026 earnings beat that has helped lift the share price toward its 52 week high.

India margins support Pfizer stock

For investors looking at Pfizer Limited in India, recent financial data compiled by a local stock portal for the period ended June 2025 show revenue of INR 603.05 crore, net income of INR 191.75 crore and a net profit margin of 31.79 percent, underlining the companys solid profitability in its domestic market.

In the same June 2025 quarter, earnings per share were reported at INR 41.91, together with EBITDA of INR 277.19 crore, indicating that the India business is generating robust cash earnings relative to its revenue base.

Global earnings beat and guidance raise

The broader Pfizer group has also provided a positive backdrop for sentiment toward Pfizer stock. According to an analyst overview, Pfizer reported second quarter 2026 revenue of USD 15.03 billion and earnings of USD negative 248 million, implying a profit margin of negative 1.65 percent for the quarter.

Despite that negative margin, market data show that on a non GAAP basis Pfizer delivered adjusted earnings per share of USD 0.77 in the same quarter, beating analyst expectations of USD 0.68 and generating a surprise of 12.87 percent, with revenue ahead of a consensus figure of USD 14.42 billion and up 2.6 percent compared with the same quarter a year earlier.

Go deeper

More on Pfizer Limited and global Pfizer results

Investors can follow detailed news and data on Pfizer Limited and the global Pfizer group via the thematic overview and the firms investor relations site.

Pfizer Limited news overview Investor Relations

Representative product portfolio in India

In India, Pfizer Limited operates with a portfolio of around 150 products across more than 15 therapeutic areas, ranging from cardiovascular and neurological disorders to vaccines and anti infectives, which gives the company a diversified revenue base that can help smooth earnings between product cycles and regulatory changes.

Stock level and investor perspective

Market data from early September 2026 indicate that the global Pfizer share has been trading close to USD 29.09, which recently matched a fresh 52 week high after the positive second quarter 2026 earnings surprise and the announcement of an adjusted full year 2026 earnings guidance range of USD 2.80 to USD 3.00 per share, with Wall Street projections clustering near USD 2.98.